Drugs /

cbp501

Back to Drugs List

Overview

NCI Definition [1]:
A peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C); disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2/cyclin B, preventing entry into the mitotic phase of the cell cycle.

Clinical Trials

View Clinical Trials for cbp501

Cbp501 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating cbp501, 1 is phase 1 (0 open).

Microsatellite Stable (MSS) is the most frequent biomarker inclusion criterion for cbp501 clinical trials.

Colorectal carcinoma and malignant solid tumor are the most common diseases being investigated in cbp501 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Cbp501
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cbp501 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
d-arginine, 4-benzoyl-d-phenylalanyl-d-seryl-d-tryptophyl-d-seryl-2,3,4,5,6-pentafluoro-d-phenylalanyl-3-cyclohexyl-d-alanyl-d-arginyl-d- arginyl-d-arginyl-d-glutaminyl-d-arginyl-, cdc25c phosphatase (211-221), cbp 501, cbp-501, serine/threonine kinase inhibitor cbp501
Drug Categories [2]:
Serine/threonine kinase inhibitors
Drug Target(s) [2]:
CHEK1, MAP3K7, MAPKAPK2
NCIT ID [1]:
C71529

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.